AbstrAct central Hypothyroidism (central H) is mainly due to acquired lesions, either in the pituitary
IntroductIon:
Hypothyroidism is a common disorder. However, the overwhelming majority of patients with hypothyroidism have thyroid disease (primary hypothyroidism, PH). Central hypothyroidism is defined as hypothyroidism due to insufficient production of TSH, caused by hypothalamic or pituitary defect. Although the exact prevalence of Central H is unknown, it is much lower than that of PH. Furthermore, patients with Central H frequently present with other pituitary hormone deficiencies, while isolated deficiency of TSH is very rare. Hashimoto 1 noted in his review that approximately sixty cases of isolated TSH deficiency had been reported since Shuman's first report in 1953. 2 Although in general practice serum TSH is the best indicator for detecting hypo-and hyperthyroidism and for monitoring treatment of thyroid disorders, this approach only works if the hypothalamic-pituitary-thyroid axis is normal. Consequently, by using TSH determination alone, patients with isolated Central H are usually missed.
We present a 54-year-old woman who presented with extreme tiredness. Hypothyroidism was suspected but it was initially excluded because of normal TSH in screening. On re-evaluation, Free Thyroxine (FT4) was low and the possibility of isolated TSH deficiency was suspected.
case report
A 54-year-old woman was referred to our clinic for a two-year history of progressive and extreme tiredness (she had even stopped working), very low energy, exhaustion after physical exercise and weight gain of 18 kg. She had no relevant family or personal past medical history, apart from menopause symptoms for which she had been on hormone replacement therapy (HRT) for the last 18 months. Reportedly, the TSH levels carried out several times by her general practitioner were normal.
On physical examination she presented very dry skin. The body mass index was 30.5 kg/m 2 and the blood pressure was normal (105/68 mmHg). Initial investigations showed normal values of serum electrolytes, urea, liver function tests, calcium and cortisol. The insulin-like growth factor (IGF-1) was low (9.22 nmol/L, normal range 10.5-35). The FT4 was also low (0.86 ng/dl, normal range 0.9-1.8). The Free Triiodothyronine (FT3) was 2.69 pg/ml (normal range: 2.3-4.3), TSH was 1.34 mIU/L (normal range 0.35-5.5) and the thyroxine-binding globulin and the thyroid peroxidase antibodies (TPO) were also within the normal range. The endocrine profile was repeated after discontinuing the HRT for 6 weeks. A low IGF-1 (8.5 nmol/L) and a low FT4 (0.87 ng/dl) with a normal FT3 (2.8 pg/ml) were detected. As there was no TSH compensatory rise (TSH: 1.46 mIU/L), and on the suggestion that she could have a pituitary cause for her hormonal deficiency, an MRI scan of the hypothalamic pituitary region was carried out, which revealed no abnormality. The rest of the pituitary function and a short Synacthen test were also normal. A thyrotropin releasing hormone (TRH) test was also performed. After 200 micrograms of TRH, a delayed response of TSH was found (Figure 1 ) (TSH at time 0: 2.3 mIU/L, TSH at 30 min: 3.4 mIU/L, TSH at 60 min: 36.2 mIU/L), indicating a possible hypothalamic defect, in the absence of a structural abnormality in the MRI. An insulin tolerance test carried out after starting thyroxine treatment showed an adequate response of cortisol and growth hormone. Finally, on the basis of these results, a diagnosis of isolated TSH deficiency was made. The patient was started on 100 micrograms of thyroxine/day and now, one year later, she is feeling well and she is clinically and biochemically euthyroid.
dIscussIon
Central hypothyroidism denotes thyroid hormone deficiency due to a disorder of the pituitary and/or hypothalamus. The etiology of central hypothyroidism is the same as for hypopituitarism. 3 Pituitary mass lesions, especially pituitary adenomas, remain the most frequent causes of Central H 4 accounting for more than half of the cases. Traumatic brain injury 5 or subarachnoid hemorrhage, bexaroteno (a retinoid X receptor agonist) 6 therapy, maternal Graves' disease insufficiently controlled and lymphocytic hypophysitis 8 are included among novel causes. Growth hormone therapy is now also recognized as a possible cause of unmasking Central H. 9 In addition, several rare gene mutations such as, TRH, TSH β, TRHR, POU1F1, PROP1, HESX1, SOX3, LHX3, LHX4 genes, the genes of leptin receptor (LEPR) and LEP have been associated with Central H. [10] [11] [12] [13] [14] Most of these genetic defects are clinically suspected, as they lead to variable phenotypes of combined pituitary hormones deficiencies and may be associated with physical abnormalities, such as septo-optic dysplasia (HESX1 mutations), hypoplasia infundibular or mental retardation (SOX3 mutations), rigid cervical spines (LHX3 mutations) and cerebellar defects or sellar abnormalities (LHX4 mutations).
15 Conversely, congenital I Central H is mainly due to genetic deficiency of the β-subunit of TSH or less frequently to mutations of the TRH or TRH receptor genes and it is usually associated with a severe form of congenital hypothyroidism if it is not treated promptly.
12-16 As our patient was an adult and had a mild hypothyroidism with normal mental development, a genetic screening was not considered necessary.
The clinical manifestations of Central H are similar to those of PH. As a result, with the use of the serum TSH assay as an initial screening test for thyroid disease, the diagnosis of Central H can be missed or delayed, because most patients have normal or even slightly high serum TSH concentrations. 17 In general, serum TSH concentrations are low in pituitary disease and normal or high in hypothalamic disease, although one cannot rely upon this generalization for a pathologic diagnosis in an individual patient. Several mechanisms leading to these differences in TSH levels have been suggested: hypoadrenalism raising serum TSH levels, decreased secretion of somatostatin from the hypothalamus resulting in increased TSH secretion, and reduced biological and receptor binding activity of TSH.
17-19
The diagnostic value of TRH stimulation has been evaluated in several studies. 20 26 or in patients with severe nonthyroidal illness. In our patient, once the presence of Central H was confirmed and other entities or critical illness were excluded, and no lesion was found in the MRI and no other hormone was altered, the unusual diagnosis of idiopathic isolated Central H was established, possibly caused by deficient TRH synthesis. 27 Because the optimum thyroxin dose for Central H is still unclear, 28 a dose similar to that given to patients with primary hypothyroidism is recommended (after excluding ACTH deficiency). The main difference in treatment between PH and Central H is that TSH cannot be used to monitor the therapy as it is suppressed to <0.1 mU/L in nearly all patients taking doses of T4 that raise their serum free T4 concentrations to normal. 29 In conclusion, Central H is an uncommon disorder which is mainly due to acquired lesions and it is usually associated with deficient secretion of other pituitary hormones. The appearance of an idiopathic isolated Central H is extremely rare and is often misdiagnosed. As routine examination of thyroid function (TSH determination) cannot easily detect it, TSH response to TRH stimulation, nocturnal surge of TSH and exclusion of more common causes of TSH 13 and the occurrence of such an entity in adulthood constitutes a novel observation. A genetic basis of an isolated TRH deficiency can not be excluded since late onset of symptoms in genetically determined disorders have been described. 30 Nevertheless in I Central H one should consider that the TSH deficiency might represent a prodromal sign of an insipient, not yet apparent, neoplastic disorder.
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